Literature DB >> 31176725

Tumor microenvironment determines drug efficacy in vitro - apoptotic and anti-inflammatory effects of 15-lipoxygenase metabolite, 13-HpOTrE.

Christopher Wolff1, Christian Zoschke1, Suresh Kumar Kalangi2, Pallu Reddanna2, Monika Schäfer-Korting3.   

Abstract

Recent studies using 3D scaffolds have emphasized the importance of the surrounding stroma on chemoresistance in drug efficacy screenings. Since 15-lipoxygenase (15-LOX) metabolites reduced growth of breast, colon, prostate, lung and leukemia cancer cells in 2D cell culture, we were intrigued by the direct comparison of 15-LOX metabolite efficacy in 2D and 3D culture including a stroma equivalent. Herein, we studied the effects of 15-LOX metabolites 13-HpOTrE, 13-HpODE, and 15-HpETE on cutaneous squamous cell carcinoma cells. All metabolites reduced the viability of cancer cells in 2D culture below 10% at 100 µM of each substance. 13-HpOTrE, being the most active agent with respect to cytotoxicity and apoptosis was selected for further experiments. Other than with the 2D culture, we did not obverse cell death, neither from lactate dehydrogenase release, nor from morphology when applying 13-HpOTrE onto the surface of the 3D tumor constructs for one week. Next, we investigated the protein expression of peroxisome proliferator activated receptor gamma, for which the ligand is 13-HpOTrE, and Bcl-2 protein, an apoptosis regulator, but did not find any change following 13-HpOTrE administration. However, 13-HpOTrE treatment reduced the release of interleukin-6, bringing it closer to the level of tumor-free constructs. In conclusion, 13-HpOTrE reduces viability of skin cancer cells in 2D cultures only but modulates inflammatory cytokine levels in the corresponding 3D tumor constructs, too. These studies highlight the need for screening of anticancer drugs employing 3D tumors and including tumor microenvironment in the screening process to increase the low success rate of clinical trials in oncology.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  13-HpOTRE; 15-Lipoxygenase; Apoptosis; Cancer; Interleukin 6; PPAR gamma

Mesh:

Substances:

Year:  2019        PMID: 31176725     DOI: 10.1016/j.ejpb.2019.06.003

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

1.  How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development.

Authors:  Monika Schäfer-Korting; Christian Zoschke
Journal:  Handb Exp Pharmacol       Date:  2021

Review 2.  Targeting Lipid Peroxidation for Cancer Treatment.

Authors:  Sofia M Clemente; Oscar H Martínez-Costa; Maria Monsalve; Alejandro K Samhan-Arias
Journal:  Molecules       Date:  2020-11-05       Impact factor: 4.411

3.  Identifying prognostic signatures in the microenvironment of prostate cancer.

Authors:  Guoliang Lu; Weijing Cai; Xiaojing Wang; Baoxing Huang; Yang Zhao; Yuan Shao; Dawei Wang
Journal:  Transl Androl Urol       Date:  2021-11

Review 4.  Ferroptosis Involvement in Glioblastoma Treatment.

Authors:  Andrei-Otto Mitre; Alexandru Ioan Florian; Andrei Buruiana; Armand Boer; Ioana Moldovan; Olga Soritau; Stefan Ioan Florian; Sergiu Susman
Journal:  Medicina (Kaunas)       Date:  2022-02-20       Impact factor: 2.430

5.  Involvement of parathyroid hormone-related peptide in the aggressive phenotype of colorectal cancer cells.

Authors:  María Belén Novoa Díaz; Pedro Matías Carriere; María Julia Martín; Natalia Calvo; Claudia Gentili
Journal:  World J Gastroenterol       Date:  2021-11-07       Impact factor: 5.742

Review 6.  The Role of Interleukins in Colorectal Cancer.

Authors:  Jingjing Li; Ling Huang; Hanzhang Zhao; Yuheng Yan; Jing Lu
Journal:  Int J Biol Sci       Date:  2020-06-14       Impact factor: 6.580

7.  Faster, sharper, more precise: Automated Cluster-FLIM in preclinical testing directly identifies the intracellular fate of theranostics in live cells and tissue.

Authors:  Robert Brodwolf; Pierre Volz-Rakebrand; Johannes Stellmacher; Christopher Wolff; Michael Unbehauen; Rainer Haag; Monika Schäfer-Korting; Christian Zoschke; Ulrike Alexiev
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.